(15) Marketing-authorization holder | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

Among the sixteen items that make up a comprehensive product information summary, item ⑮ covers the "name and address of the marketing authorization holder." It looks like a plain contact box, but the spirit of the foreword lives here in concrete form. Every individual claim made in a piece of material ultimately leads back to a single question: who is accountable, and where can a reader go to check it? Marking that location is the job of this item.

The foreword positions the product information summary as material that supplements the package insert, and demands that accuracy and verifiability be guaranteed structurally. Together with ⑭ Principal References and ⑯ Date of Preparation or Revision, item ⑮ forms the closing trio that physically supports that "verifiability." Only when the basis (references), the version (date), and the responsible party and contact point (this item) are all present can a reader trace a statement back and confirm it.

01What is recorded — the responsible party and the address

What is written here is the name and address of the company that markets the drug. For a corporation, the address is the location of the office where the marketing supervisor-general carries out their duties — not merely the registered headquarters, but the place where the person who oversees quality and safety management actually works. This matters because, under the Pharmaceuticals and Medical Devices Act, ultimate responsibility for marketing rests with the marketing authorization holder, and the marketing supervisor-general is at the center of that responsibility. The address field should be read as a declaration: "the working base that bears final responsibility for the quality of this information is here."

For products involving several companies — a launching company, a distributor, an allied partner — each may be listed together. With prescription drugs it is not unusual for the marketing authorization holder and the company that handles sales to differ, or for several firms to appear because of in-licensing or partnership arrangements. So that readers do not mistake "which is the contact point" or "who is the responsible party," related companies are permitted to be shown side by side.

02Why specify the address at all

If a company name alone were enough, an advertising credit would suffice. The reason the Creation Guide insists on the address, and pins it specifically to the office of the marketing supervisor-general, is that it treats this box not as decoration but as the "location of responsibility." Inquiries about safety information, reports of adverse reactions, confirmation of references — none of these work unless there is a real, reachable destination. The foreword's "duty to convey accurate information to healthcare professionals" is only complete when there is a receiving point ready to take inquiries after the information has been conveyed.

If the contact point is hollow, the route for correction is cut off the moment a misunderstanding or question arises. The Guide's design philosophy of closing off "true but misleading" expressions only holds together if there is a window where healthcare professionals can verify and inquire after a misunderstanding occurs. An inaccurate or outdated contact listing is not a mere clerical slip — it can amount to a loss of verifiability itself.

03The case of a foreign special-approval holder

For a drug where an overseas company holds the approval as a foreign special-approval holder, the requirement grows one step heavier. In addition to the name and address of the designated marketing company that handles operations domestically, the name of the foreign special-approval holder and the country in which its address is located must also be written.

The reason lies in a two-layer structure of responsibility. The overseas entity that holds the approval in its name and the designated company that carries domestic marketing responsibility and serves as the contact point are different bodies; for a healthcare professional, the domestic designated company is the realistic first port of call. At the same time, knowing which country the entity holding the approval belongs to is indispensable for understanding the product's origin and where final responsibility ultimately rests. By showing both the domestic window and the overseas approval-holder, it becomes clear both whom to contact and who bears final responsibility.

How the designated marketer and the approval holder differ in role

Aspect	Designated marketer (domestic)	Foreign special-approval holder (overseas)
Role	Domestic marketing operations, responsibility, and contact window	Entity that holds the approval in its name
What is recorded	Name and address	Name and the country of its address
Position from the professional's view	The realistic first point of inquiry	The product's origin and seat of final responsibility

04Literature-request and inquiry contacts

This item also records the literature-request contact and the inquiry contact. Even when ⑭ Principal References shows where the basis lies, it cannot be called "verifiable" unless there is a destination from which that literature can actually be requested. The reason a responsible department and its contact details may be listed alongside is that reaching the section that actually handles the documents directly is more effective for inquiries than going through the company's general window.

Read ⑭ Principal References as the box that shows "what the basis is," and ⑮ as the box that shows "where to request that basis and address questions about it," and the relationship between the two becomes clear. The former alone gives only the name of the source. Only when the latter accompanies it can a healthcare professional actually carry out the cross-check behind a statement.

Connection to the "upon request" spirit

Throughout the Guide, material such as article reprints and abstract collections must be provided in response to a healthcare professional's request, not pushed. Clearly stating the inquiry and literature-request contacts is also the entrance that makes that "upon request" relationship possible. Rather than a company delivering one-sidedly, it prepares a route by which professionals who need the information can come to confirm it themselves — listing the contact serves, as a matter of structure, to support that receptive posture.

In closing

Item ⑮ carries no flashy prohibition. Yet by placing the responsible party and its address, the two-layer naming for overseas approvals, and the literature-request and inquiry destinations accurately, it ties everything written in the material back to "whom should I ask to confirm this." When the basis (⑭), the window (⑮), and the version (⑯) are all present, the product information summary stops being a closed piece of promotion and becomes an open document that can be checked after the fact.

The quiet, accumulating work of keeping contact details current and accurate is what underpins the foreword's duty to "convey accurately, without misleading."

Case studies — the "it isn't written, so…" mindset, and how each lands

If the responsible party cannot be positively identified, adverse-event queries and product recalls both break down. Four levels of how contact information can be made ambiguous.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "The marketing authorisation is held by a subsidiary, but the materials list only the parent holding company name and address. The group halo is useful, and 'it's the same group' is the fallback argument."

Verdict: Spirit violation. The purpose of listing the marketing authorisation holder is to establish legal accountability and a reachable enquiry point. The parent holding company does not hold a PMD Act marketing authorisation; listing only its name leaves readers unable to reach the correct contact. The subsidiary holding the authorisation must be the primary entry; the group name is a supplementary note at most.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "After a head-office relocation, the old address continues to appear in materials. The package insert has been updated, but revising the product summary is deferred as too costly. 'The insert is the authoritative document; we'll fix the summary eventually.'"

Verdict: Gap exploit. Medical institutions sending recall-response correspondence to the old address will not reach the company. If phone and fax numbers have also changed, all enquiry channels may be severed simultaneously. The foreword's concept of supplementation requires that materials remain independently functional for enquiries. Update the product summary address at the same time as the package insert.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "For an imported product, list only the foreign manufacturer's name, omitting the domestic marketing authorisation holder. Rationalised as 'the manufacturer bears the fundamental responsibility.'"

Verdict: Higher-norm violation. The PMD Act marketing authorisation holder is a domestic legal entity and is the responsible party for adverse-event reporting, recalls, and regulatory correspondence. The foreign manufacturer's listing is supplementary only. The JPMA Code requires an explicit domestic contact point. List the domestic marketing authorisation holder as the primary entry and the manufacturer in parentheses as supplementary.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "Record a trade abbreviation for the marketing authorisation holder that differs from the exact legal name in the approval certificate (e.g., approval reads 'A Pharmaceutical Co., Ltd.' but the material says 'A Pharma')."

Verdict: Explicit breach. The guidelines require the marketing authorisation holder's name exactly as stated in the approval certificate. An abbreviation makes it difficult to cross-reference against PMD Act licence numbers and constitutes inaccurate transcription of a mandatory item. Use the exact name from the approval certificate and licence documentation.

Improper intent by implication — three scopes of "insinuating" without stating it

Item ⑮ (marketing authorization holder's name and address) exists to keep contact information accessible for verification. Yet through embedding corporate achievements in the name field, pairing contact details with organizational scale, and populating the section with group-company profiles, it can silently sell corporate credibility rather than product information.

Implication 1 — Local: carried in a single word or sentence

How it is built: "Marketing authorization holder: XX Pharmaceutical Co., Ltd. (operations in 50 countries worldwide)"

Intent that can be read: "Operations in 50 countries worldwide" is neither an address nor a contact reference — it is an advertisement for international scale appended directly after the company name, making the scale claim feel like a factual attribute of the entity.

Verdict: This item permits only the company name, registered address, and contact information. Corporate footprint, history, and accolades are unrelated to product information and constitute promotional additions prohibited by the guidelines. Only the name and address should appear.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: "Marketing authorization holder: XX Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo). 24-hour dedicated support centre for healthcare professionals. Headquarters co-located with global R&D centre."

Intent that can be read: Two sentences placed beside the contact address — one about service availability, the other about research infrastructure — together construct an impression of organisational reliability and technical capacity, converting it into confidence in the product.

Verdict: The availability of 24-hour support is marginal product-contact information and may be acceptable; a reference to a "global R&D centre" is a research-capability promotion and is not. The pairing of the two creates a cumulative corporate endorsement that exceeds what this item permits.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: Item ⑮ lists the marketing authorization holder, the contract manufacturer, and an affiliated foreign company, each followed by year of establishment, headcount, and certification held.

Intent that can be read: The contact section becomes a group corporate profile. As the final item readers encounter, it closes the document by imprinting corporate scale and credibility rather than product information — a silent piece of corporate branding.

Verdict: Year of establishment, headcount, and certification data are all outside the permitted scope of Item ⑮. Including them converts the closing section into a corporate advertisement — a structural violation. The guidelines require product information to be complete and verifiable; all company information beyond the contact address must be removed.